Arnulf Ferlitsch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4924134/publications.pdf

Version: 2024-02-01

99 4,689 39 66
papers citations h-index g-index

101 101 101 4594 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Nonselective \hat{I}^2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology, 2014, 146, 1680-1690.e1.	0.6	336
2	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut, 2013, 62, 1634-1641.	6.1	275
3	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. Journal of Hepatology, 2013, 58, 911-921.	1.8	269
4	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. Journal of Hepatology, 2016, 65, 692-699.	1.8	245
5	Evaluation of a Virtual Endoscopy Simulator for Training in Gastrointestinal Endoscopy. Endoscopy, 2002, 34, 698-702.	1.0	162
6	Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology, 2012, 56, 1439-1447.	3.6	158
7	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. European Journal of Radiology, 2012, 81, 4112-4118.	1.2	156
8	Preemptiveâ€TIPS Improves Outcome in Highâ€Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	3.6	144
9	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. Journal of Hepatology, 2020, 73, 1082-1091.	1.8	112
10	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver International, 2015, 35, 381-390.	1.9	111
11	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothÂIII). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.0	111
12	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. American Journal of Gastroenterology, 2021, 116, 723-732.	0.2	105
13	Safety and Efficacy of Endoscopic Balloon Dilation for Treatment of Crohn's Disease Strictures. Endoscopy, 2006, 38, 483-487.	1.0	100
14	Non-selective Î ² -blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. Journal of Gastroenterology, 2012, 47, 561-568.	2.3	97
15	Noninvasive screening for liver fibrosis and portal hypertension by transient elastographyâ€"a large single center experience. Wiener Klinische Wochenschrift, 2012, 124, 395-402.	1.0	93
16	The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study. Alimentary Pharmacology and Therapeutics, 2012, 35, 83-91.	1.9	83
17	Interferonâ€free regimens improve portal hypertension and histological necroinflammation in <scp>HCV</scp> patients with advanced liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 139-149.	1.9	83
18	6-Thioguanine Associated Nodular Regenerative Hyperplasia in Patients With Inflammatory Bowel Disease May Induce Portal Hypertension. American Journal of Gastroenterology, 2007, 102, 2495-2503.	0.2	80

#	Article	IF	CITATIONS
19	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Alimentary Pharmacology and Therapeutics, 2018, 47, 980-988.	1.9	78
20	Evaluation of Portal Hypertension and Varices by Acoustic Radiation Force Impulse Imaging of the Liver Compared to Transient Elastography and AST to Platelet Ratio Index. Ultraschall in Der Medizin, 2014, 35, 528-533.	0.8	75
21	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver International, 2015, 35, 2121-2128.	1.9	72
22	The profile of platelet αâ€granule released molecules affects postoperative liver regeneration. Hepatology, 2016, 63, 1675-1688.	3.6	67
23	Effect of virtual endoscopy simulator training on performance of upper gastrointestinal endoscopy in patients: a randomized controlled trial. Endoscopy, 2010, 42, 1049-1056.	1.0	63
24	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Radiology, 2015, 277, 903-912.	3.6	60
25	The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test. PLoS ONE, 2016, 11, e0149230.	1.1	58
26	Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2011, 9, 602-608.e1.	2.4	57
27	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. PLoS ONE, 2014, 9, e110503.	1.1	55
28	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. Liver International, 2015, 35, 2115-2120.	1.9	54
29	Serum bile acids as marker for acute decompensation and acuteâ€onâ€chronic liver failure in patients with nonâ€cholestatic cirrhosis. Liver International, 2017, 37, 224-231.	1.9	47
30	The value of different CTâ€based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver International, 2019, 39, 2374-2385.	1.9	47
31	Diamond Stents for Palliation of Malignant Bile Duct Obstruction: A Prospective Multicenter Evaluation. Endoscopy, 2001, 33, 645-650.	1.0	44
32	Interferonâ€free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Alimentary Pharmacology and Therapeutics, 2015, 42, 707-718.	1.9	44
33	Low 25-OH-vitaminÂD levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. Wiener Klinische Wochenschrift, 2017, 129, 8-15.	1.0	44
34	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wiener Klinische Wochenschrift, 2013, 125, 200-219.	1.0	43
35	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. Journal of Hepatology, 2014, 61, 544-549.	1.8	43
36	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. Digestive and Liver Disease, 2015, 47, 144-150.	0.4	43

#	Article	IF	CITATIONS
37	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Alimentary Pharmacology and Therapeutics, 2018, 47, 966-979.	1.9	41
38	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wiener Klinische Wochenschrift, 2018, 130, 446-455.	1.0	41
39	Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. Hepatology, 2018, 67, 1516-1530.	3.6	39
40	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver International, 2019, 39, 127-135.	1.9	39
41	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1657-1665.	1.4	37
42	Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 47, 86-94.	1.9	36
43	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a doseâ€response study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1162-1169.	1.9	33
44	Revisiting liver disease progression in HIV/HCVâ€coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver International, 2015, 35, 876-885.	1.9	32
45	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver International, 2018, 38, 1427-1436.	1.9	31
46	Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Critical Care Medicine, 2005, 33, 2028-2033.	0.4	29
47	Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. British Journal of Cancer, 2016, 115, 1421-1429.	2.9	29
48	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease, 2017, 49, 1360-1367.	0.4	28
49	ePTFEâ€ŢIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver International, 2018, 38, 1036-1044.	1.9	28
50	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	1.8	28
51	A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV–HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin. Antiviral Therapy, 2012, 17, 1327-1334.	0.6	27
52	Impact of patatinâ€ike phospholipase domain containing <i>3 rs738409</i> Â <i>G/G</i> genotype on hepatic decompensation and mortality in patients with portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 48, 451-459.	1.9	26
53	High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. Endoscopy, 2015, 47, 207-216.	1.0	25
54	Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. Gastrointestinal Endoscopy, 2019, 89, 496-502.	0.5	25

#	Article	IF	CITATIONS
55	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. Ultrasound in Medicine and Biology, 2015, 41, 2340-2349.	0.7	23
56	Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?. Endoscopy, 2015, 47, 898-902.	1.0	23
57	Liver disease in adults with α1â€antitrypsin deficiency. United European Gastroenterology Journal, 2018, 6, 710-718.	1.6	23
58	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Digestive and Liver Disease, 2019, 51, 1144-1151.	0.4	23
59	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience. PLoS ONE, 2018, 13, e0189414.	1.1	20
60	Impact of <i>HSD17B13 rs72613567</i> genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver International, 2020, 40, 393-404.	1.9	20
61	Management of Coagulopathy during Bleeding and Invasive Procedures in Patients with Liver Failure. Visceral Medicine, 2018, 34, 254-258.	0.5	19
62	Nonâ€invasive diagnosis of cirrhosis and longâ€term disease monitoring by transient elastography in patients with Wilson disease. Liver International, 2020, 40, 894-904.	1.9	19
63	Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2005, 21, 49-55.	1.9	18
64	Short―and longâ€ŧerm effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. United European Gastroenterology Journal, 2019, 7, 850-858.	1.6	18
65	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 184-190.	1.4	17
66	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. Hepatology Research, 2019, 49, 201-211.	1.8	16
67	A Greater Proportion of Liver Transplant Candidates Have Colorectal Neoplasia Than in the Healthy Screening Population. Clinical Gastroenterology and Hepatology, 2015, 13, 956-962.	2.4	15
68	Effects of Portal Hypertension on Gadoxetic Acid–Enhanced Liver Magnetic Resonance. Investigative Radiology, 2017, 52, 462-469.	3.5	14
69	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	0.6	13
70	Impact of highâ€volume, intermediateâ€volume and lowâ€volume bowel preparation on colonoscopy quality and patient satisfaction: An observational study. United European Gastroenterology Journal, 2019, 7, 114-124.	1.6	13
71	von Willebrand Factor Antigen: A Novel On-Treatment Predictor of Response to Antiviral Therapy in Chronic Hepatitis C Genotypes 1 and 4. Antiviral Therapy, 2010, 15, 831-839.	0.6	12
72	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1619-1627.	1.4	12

#	Article	IF	CITATIONS
73	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound in Medicine and Biology, 2018, 44, 2578-2586.	0.7	11
74	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver International, 2016, 36, 1649-1656.	1.9	10
75	Endoscopic versus surgical management of biliary complications – Outcome analysis after 1188 orthotopic liver transplantations. Digestive and Liver Disease, 2016, 48, 1323-1329.	0.4	10
76	The impact of hepatic steatosis on portal hypertension. PLoS ONE, 2019, 14, e0224506.	1.1	10
77	Combination of phosphodiesteraseâ€5â€inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver International, 2020, 40, 2228-2241.	1.9	9
78	von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma. Gut and Liver, 2020, 14, 218-224.	1.4	9
79	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. Digestive Diseases and Sciences, 2019, 64, 3642-3651.	1.1	8
80	Endoscopic imaging of the vermiform appendix (with video). Gastrointestinal Endoscopy, 2014, 80, 1156-1160.	0.5	5
81	Liver Biopsy-Transjugular. Clinical Liver Disease, 2014, 4, 113-115.	1.0	5
82	A novel endoscopic device for repeated right-side colonic access during colonoscopy (with video). Gastrointestinal Endoscopy, 2010, 71, 1052-1055.	0.5	1
83	Letter: sorafenib in portal hypertension – authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 994-995.	1.9	1
84	Efficacy and safety of bovine activated factors IIa/VIIa/IXa/Xa in patients with active gastrointestinal bleeding: a proof of concept study. Endoscopy, 2016, 48, 380-384.	1.0	1
85	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Digestive and Liver Disease, 2016, 48, 1194-1199.	0.4	1
86	Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosisâ€"Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1537-1538.	1.9	1
87	Prescintigraphic morphine application for abdominal adenocarcinoma imaging, with technetium-99m methoxy isobutyl isonitrile. Hellenic Journal of Nuclear Medicine, 2007, 10, 14-8.	0.2	1
88	Reply. Hepatology, 2013, 58, 1189-1190.	3.6	0
89	Editorial: getting bullish about portal hypertensionâ€"chronic treatment with oral taurine? Author's reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 534-535.	1.9	0
90	Editorial: optimal dose of carvedilol in portal hypertension… nearly there. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1329-1330.	1.9	0

#	Article	IF	CITATIONS
91	Editorial: surviving your genesâ€"the role of <i><scp>PNPLA</scp>3</i> variation in endâ€stage liver disease. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 775-776.	1.9	0
92	IMPROVING THE ADENOMA DETECTION RATE CONTINUOUSLY: IS IT WORTH THE EFFORT?. Endoscopy, 2018, 50, .	1.0	0
93	Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2018, 56, .	0.2	0
94	The impact of hepatic steatosis on portal hypertension. Zeitschrift Fur Gastroenterologie, 2018, 56, .	0.2	0
95	Prevalence and Resistance Rates of Infections with Enterococci in Patients with Cirrhosis., 2018, 56, .		0
96	Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information. , 2018, 56, .		0
97	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. , $2018, 56, .$		0
98	The value of different CT-based methods for diagnosing sarcopenia and predicting mortality in patients with cirrhosis. , $2019, 57, \ldots$		0
99	DIFFERENCES IN BOWEL PREPARATION QUALITY BETWEEN IN- AND OUTPATIENTS UNDERGOING SCREENING COLONOSCOPY. Endoscopy, 2020, 52, .	1.0	0